Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach.
Turner
C D
CD
Department of Surgery, University of Chicago, Illinois, USA.
Bruce
D S
DS
Cronin
D C
DC
Loss
G E
GE
Grewal
H
H
Siegel
C
C
Millis
J M
JM
Newell
K A
KA
Davis
B
B
Todo
T
T
Thistlethwaite
J R
JR
Woodle
E S
ES
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D001707:Biopsy, Needle; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D016559:Tacrolimus